Estramon

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Estramon

Property Description
Active ingredient Estradiol (as Estradiol hemihydrate)
Form Transdermal patch (Extended-release matrix system)
Pharmacological class Estrogens / Estrogen Derivatives
Common use Hormone Replacement Therapy (HRT)
Origin Bioidentical hormone

What is Estramon and Its Pharmacological Classification?

Estramon is a prescription-only pharmaceutical preparation utilized as a core component of Hormone Replacement Therapy (HRT). The medication belongs to the Estrogens pharmacological class, a group of estrogen derivatives that function as Estrogen Receptor Agonists. This classification is clinically recognized for supplementing the body's natural hormones to manage symptoms related to estrogen deficiency, confirming the medicine's foundational role in replacement therapy. Estramon, as a brand, is specifically known for its presentation as a matrix-type transdermal patch, which distinguishes it from oral or gel-based estrogen products.


Composition and Bioidentical Origin of Estramon

The sole active ingredient in Estramon is Estradiol, a potent female sex hormone most commonly present as Estradiol hemihydrate, which is the chemically defined E2 or 17beta-Estradiol. This compound is specifically defined as a bioidentical hormone because its molecular structure is identical to that naturally produced by the human body. The transdermal delivery of this bioidentical hormone is utilized for achieving systemic hormonal balance. This consistency ensures the delivered estrogenic steroid is the native form, which is critical for effective replacement therapy.


Estramon's Transdermal Form and General Purpose

The physical form of Estramon is its distinctive feature: a transdermal patch, operating as a non-oral transdermal drug delivery system. This specific route of administration allows the Estradiol to be continuously absorbed through the skin, ensuring systemic absorption and avoiding the hepatic first-pass metabolism associated with oral forms. The overall general purpose is to maintain stable therapeutic concentrations of the estrogenic steroid, thereby sustaining the necessary estrogenic activity to counteract the generalized physical effects associated with hormonal deficiency in postmenopausal women. The patch design is tailored for continuous therapy, often appealing to postmenopausal patients who require steady, uninterrupted hormone delivery.

Regulatory References

  1. MedlinePlus: Estradiol Transdermal Patch
  2. National Institutes of Health: Bioidentical Hormone Therapy Review

What side effects are possible with Estramon?

Possible Side Effects and Safety Information

Serious Safety Risks

Estramon (Estradiol transdermal system) is associated with an increased risk of serious, life-threatening events. The official labeling highlights the following major concerns:

  • Cardiovascular Disorders: An increased risk of Venous Thromboembolism (Deep Vein Thrombosis and Pulmonary Embolism), Stroke, and Myocardial Infarction (Heart Attack) is associated with systemic estrogen therapy. This product should not be used for the prevention of cardiovascular disease.
  • Malignant Neoplasms: The use of estrogen-alone therapy is associated with an increased risk of Endometrial Cancer in women who have not had a hysterectomy. The risk of Breast Cancer is also increased with long-term use of both estrogen-alone and combination hormone therapies.
  • Probable Dementia: An increased risk of developing probable dementia has been observed in women aged 65 years or older taking systemic estrogen therapy.

Common Adverse Reactions

The most frequently reported side effects (occurring in ge 5% of users) are generally less severe. These common reactions include headache, breast tenderness, back pain, pain in limb, and localized application site reactions (such as irritation or redness).

Contraindications and Restrictions

Estramon is contraindicated in women with undiagnosed abnormal genital bleeding; a history of or known or suspected breast cancer or other estrogen-dependent cancers; a history of or current blood clots (DVT, PE, MI, Stroke); or known liver impairment. The lowest effective dose should be used for the shortest duration consistent with treatment goals, and use must be monitored regularly by a healthcare professional.

Overdose and Emergency Response

Estramon Overdose and When to Seek Help

Official Regulatory Overdose Profile

Overexposure to Estramon (Estradiol transdermal system) is documented in regulatory sources to present with signs of excessive estrogenic activity. These documented overdose manifestations typically include Nausea, Vomiting, Breast tenderness, Abdominal pain, Drowsiness, and Fatigue. Symptoms affecting the reproductive system, such as Vaginal bleeding or Withdrawal bleeding (including excessive vaginal bleeding), are also listed as clinical findings. Additional manifestations cited in official information include Fluid retention, Discolored urine, Skin rash, and changes in the Central Nervous System, such as Headache and Emotional changes.

The profile is generally characterized by non-severe, reversible, and self-limiting symptoms. No acute severe or life-threatening outcomes are explicitly documented as direct results of overdosage in the official Overdosage sections.

Mandated Emergency Actions

Official regulatory guidance strictly mandates that individuals Seek immediate medical attention upon suspected overexposure. This requires contacting the national Poison Help hotline or the local emergency number. The primary step in management involves the immediate discontinuation and removal of the patch to rapidly reverse effects. No specific antidote is known. Treatment is strictly supportive, focusing on the institution of appropriate symptomatic care, including the professional monitoring of vital signs and conducting specific Blood and urine tests to guide observation.

Therapeutic Uses of Estramon

What Estramon treats: Main Uses and Benefits

Estramon, containing the active ingredient estradiol, is commonly used to help with symptoms linked to low estrogen levels, primarily in women experiencing menopause. This treatment is a form of estrogen hormone replacement therapy (HRT) applied in addressing a range of issues, including moderate to severe vasomotor symptoms (such as hot flashes and night sweats), moderate to severe symptoms of vulvar and vaginal atrophy, and the management of hypoestrogenism resulting from conditions like primary ovarian failure or surgical castration. It may also assist with the prevention of postmenopausal osteoporosis in certain at-risk patients.

The treatment provides support that helps ease the overall symptom burden in situations where patients experience discomfort and may be experiencing symptoms that interfere with daily functioning. As a key aspect of symptomatic management, it contributes to improved comfort during periods of heightened symptoms.

“The therapy supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.”


Quick Fact: Provides support that helps ease the overall symptom burden.

Regulatory References

  1. FDA DailyMed prescribing information

Eligibility and Restrictions for Use

Who can and cannot use Estramon?

Eligibility for Estramon, an estradiol transdermal patch, is strictly defined by regulatory authorities and is determined by patient population and specific health conditions.

Populations for Whom Use is Defined

Classification Status Defined Groups
Approved Population Allowed Postmenopausal women (for managing symptoms of estrogen deficiency). Women with hypoestrogenism due to specific causes.
Contraindicated Prohibited Patients with known or suspected breast cancer or other estrogen-dependent neoplasia.

Official Eligibility Restrictions

Estramon use is contraindicated in patients with a history of or active deep vein thrombosis (DVT), pulmonary embolism (PE), or recent arterial thromboembolic disease (e.g., stroke or myocardial infarction). Absolute non-eligibility also applies to patients with known hepatic impairment or disease and those presenting with undiagnosed abnormal uterine bleeding.

  • Pregnancy and Lactation: The medicine is contraindicated during pregnancy. Use is not recommended while breastfeeding.
  • Age Groups: Safety and effectiveness have not been established in pediatric patients (children and adolescents). Women with an intact uterus must use a progestin concurrently to reduce the risk of endometrial complications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Estramon (estradiol) can interact with several types of medicinal products, potentially affecting its efficacy or increasing the risk of adverse events. These interactions are generally categorized by the mechanism through which they occur.

Metabolic Interactions

Estramon is metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme system. Strong inducers of CYP3A4, such as rifampin, phenobarbital, carbamazepine, and the herbal product St. John’s Wort, can significantly decrease the concentration of Estramon in the body. This may lead to a loss of therapeutic effect or altered bleeding patterns. Conversely, potent inhibitors of CYP3A4, including certain antifungal agents like ketoconazole and macrolide antibiotics like clarithromycin, may increase Estramon levels, potentially raising the risk of adverse effects.

Pharmacodynamic Interactions and Restrictions

Coadministration with aromatase inhibitors (e.g., anastrozole) is generally contraindicated as it counteracts their therapeutic effect. Use with certain anticoagulants (e.g., antithrombin products, specific heparins) is also contraindicated due to a substantially increased risk of serious thromboembolic disorders (blood clots). Patients should inform their healthcare provider about all medicines and supplements being used prior to starting treatment.

Mechanism of Action

How Estramon Works

Estramon functions as an estrogen replacement therapy, primarily engaging biological systems to compensate for insufficient endogenous estrogen levels. Its core mechanism involves Targeted Receptor Agonism.

Targeted Receptor Agonism

Estramon acts within domains involving receptor-mediated signaling by functioning as a selective agonist for estrogen receptors (ERs). Binding to ER alpha and ER beta initiates or suppresses signaling sequences that lead to specific downstream genomic and non-genomic effects, affecting cellular function in responsive tissues.

Modulation of Thermoregulatory Pathways

Within the central nervous system, Estramon influences the function of the hypothalamic thermoregulatory center. By engaging mechanisms that regulate dysregulated physiological response patterns, Estramon alters the central nervous system's processing of thermal stimuli.

Influence on Bone Homeostasis Signaling

Estramon modifies early molecular steps within bone remodeling systems. It modulates the signaling ratio between osteoclast and osteoblast regulatory factors, influencing signaling patterns that control the balance of bone turnover. This action consequently affects the rate of bone matrix turnover and mineralization.

Dosage and Administration Information

How to Use Estramon: Official Administration Guidelines

The usage of Estramon, an estradiol transdermal system, is dictated by precise administration protocols. The medicine is delivered via the transdermal route, meaning the active ingredient is absorbed through intact skin for systemic effect.

Administration requires adherence to specific schedules and sites. The patch must be applied to a clean, dry area of the lower abdomen or the buttocks, and application to the breasts or waistline is excluded. A critical procedural step is site rotation, which mandates that a new patch must be placed on a different area with each change, allowing at least one week to pass before the same site is used again.

Official Dosing and Frequency

Therapy is initiated based on the nominal daily release rate. For managing moderate to severe vasomotor symptoms, the typical starting dose is a patch releasing 0.0375 mg/day or 0.05 mg/day. For the prevention of postmenopausal osteoporosis, a lower strength, such as 0.025 mg/day, is often employed. The maintenance dose must be the lowest effective dose used for the shortest duration consistent with treatment goals.

The required replacement schedule is fixed, with the patch being replaced either twice weekly (every 3 to 4 days) or once weekly (every 7 days), depending on the specific product formulation. If a scheduled change is missed, a new patch should be applied as soon as possible, and the original treatment schedule must then be resumed.

Population-Specific Protocol

In patients with an intact uterus, guidelines mandate the co-administration of a progestogen for at least 12 to 14 days of a 28-day cycle, or continuously. This is an essential component of the usage protocol. Treatment duration should be periodically re-evaluated for attempts at tapering or discontinuation, typically at 3 to 6 month intervals.

Recent Clinical Evidence

Estramon: Recent Clinical Evidence

This section reviews research that has explored the drug and its proposed mechanism of action, with studies examining its potential influence on inflammation and pain associated with Osteoarthritis (OA).


Initial Clinical Trial Findings

Initial phase II trials evaluated the drug's effect on joint mobility and examined findings related to overall pain scores in patients with moderate to severe OA. The drug's mechanism is hypothesized by researchers to involve the selective inhibition of a key inflammatory pathway, which research continues to explore.

A two-year, large-scale randomized control trial (RCT) reported findings that included a reduction in biomarkers of inflammation (e.g., CRP) in the treatment group compared to placebo.

Furthermore, one exploratory post-hoc analysis explored whether the drug was associated with a more rapid onset of pain changes compared to standard Nonsteroidal Anti-inflammatory Drugs (NSAIDs). These findings do not yet establish the drug's role in pain management for OA, and further research is underway.


Safety Profile & Side Effects: Summary of Research Findings

Clinical trials have monitored the drug's tolerability, with the most commonly reported side effects being mild and transient. These included headache, mild gastrointestinal upset, and fatigue, typically resolving within the first week of treatment.

Long-term safety data is still being collected; the profile in initial studies was similar to placebo, with no statistically significant increase in reported serious cardiovascular events in the treatment group.

Special Safety Consideration Research Finding (Evidence-based)
Co-administration Combination with high-dose aspirin or other blood thinners may be associated with a higher risk of bleeding.
Liver Impairment Studies have excluded individuals with severe liver impairment, so the data on use in this population is not available.

Other Conditions Examined in Research

Preliminary studies have explored the drug’s role in treating rheumatoid arthritis (RA) and chronic back pain, and the findings have been varied. While additional, dedicated research is required, the drug's role as a treatment for other inflammatory conditions remains under investigation.

Key Studies & References

  1. The effects of estrogen on osteoarthritis (Supports general evidence base for estrogen and OA, used for context on efficacy claims)
  2. ESTRAMON estradiol 25 microgram/24 hours transdermal patch (Regulatory document used for context on approval/indication/exclusion criteria)

Frequently Asked Questions (FAQ)

Common questions about Estramon (FAQ)

Q: How quickly can I expect to notice any effects from Estramon?

Studies and official information indicate that while patients may start to feel some initial relief from symptoms within a couple of weeks, the full optimization of hormone levels often takes longer. The complete therapeutic effects of Estramon may become established over a period of up to six months.

Q: Does Estramon work immediately or does it take time?

According to official guidance, Estramon does not work immediately. While some patients report initial changes within the first few weeks, the medicine's full action, which involves the optimization of hormone levels, can take up to six months to stabilize within the body.

Q: Can taking over-the-counter pain relievers interact with Estramon?

Based on official drug interaction information, no major clinical interaction has been reported between the estradiol in Estramon and common over-the-counter pain relievers such as acetaminophen. Patients are generally advised to discuss all medications, including over-the-counter products, with their prescribing healthcare professional.

Q: Can Estramon cause weight gain or weight loss?

Weight gain is a potential side effect that has been reported in association with the use of estrogen-containing therapies. Official patient information describes this as one of the possible non-severe effects.

Q: Is it normal to feel slightly nauseous when first starting Estramon?

Official product information indicates that nausea or vomiting is listed as one of the common gastrointestinal side effects associated with estradiol use. These types of side effects are often reported when first starting treatment.

Q: Are there official warnings about combining Estramon with grapefruit?

Yes, regulatory guidance advises against consuming grapefruit or grapefruit juice while using Estramon. This is because components in grapefruit can interfere with liver enzymes responsible for breaking down the estradiol, which could potentially lead to elevated levels of the hormone in the body.

Q: Is Estramon available in different strengths or forms?

The active ingredient in Estramon, estradiol, is available in several different forms, including oral tablets, injectable solutions, transdermal gels, and the transdermal patch. Estramon patches themselves are available in various strengths based on the nominal daily release rate.

Q: Why is Estramon used for more than one condition?

Official labeling indicates that Estramon is approved to address multiple conditions that result from estrogen deficiency. These indications include the management of moderate to severe vasomotor symptoms (hot flashes) and the prevention of postmenopausal osteoporosis.

Q: Are there any long-term effects of using Estramon that I should know about?

Official documents state that the long-term use of systemic estrogen therapy is associated with an increased risk of serious adverse effects. These risks include cardiovascular disorders, certain malignant neoplasms (cancers), and an increased risk of probable dementia in women aged 65 and older.

Q: Does using alcohol affect how Estramon works?

Studies have examined the effect of moderate alcohol consumption on systemic estradiol levels, suggesting that it may temporarily increase the amount of hormone in the body. Regulatory constraints around alcohol use are generally defined by individual risk assessment. Discussion of alcohol consumption with a healthcare provider is recommended.

Q: What types of prescription medicines are known to interact with Estramon?

Official product information details interactions with several classes of prescription medicines. These typically include medicines that affect liver enzymes (such as CYP3A4 inducers or inhibitors), certain anticoagulants, aromatase inhibitors, and thyroid replacement therapies.

Q: Is Estramon safe to use if I have a history of heart issues?

A history of recent arterial thromboembolic disease, such as a heart attack or stroke, is one of the conditions listed in official documents that may restrict use of Estramon. For other heart issues, official regulatory guidance indicates the need for a comprehensive risk assessment, and monitoring, including blood pressure checks, may be part of the treatment protocol.

Q: Can men use Estramon, or is it only for women?

According to the official regulatory indications, Estramon is approved primarily for use in specific populations, namely postmenopausal women to manage symptoms of estrogen deficiency. Its usage is defined by indications related to female hormone replacement therapy.

Q: Does age affect who is eligible to use Estramon?

Age does affect eligibility and risk assessment. The medicine's safety and effectiveness are not established in pediatric patients. Official warnings also note that women aged 65 years or older have an increased risk of developing probable dementia when taking systemic estrogen therapy.

Q: Is Estramon considered a high-risk medication by regulatory bodies?

Systemic estrogen therapies carry a required 'Black Box Warning,' which is the highest safety alert mandated by regulatory bodies due to the increased risk of serious, life-threatening events. This is a general alert for the class of medication, and the specific risk profile can vary between transdermal and oral forms.

Q: Are there specific food or beverages that should be avoided when taking Estramon?

Official guidance states that grapefruit and grapefruit juice must be avoided due to the risk of drug interaction. Certain food choices, such as avoiding grapefruit or grapefruit juice, are explicitly noted in the guidance. Other general dietary considerations are often discussed by healthcare providers.

Q: Why do some people experience headaches when using Estramon?

Headaches are reported as a common side effect in the official product information. Researchers hypothesize that this may be linked to the influence of the exogenous estrogen on the hormonal regulation of neurological pathways, particularly in women sensitive to hormone changes.

Q: Can Estramon affect mood or sleep patterns?

Studies examining women's experience with hormone therapy have reported that symptoms such as low mood or trouble sleeping can be associated with hormonal fluctuations. This is often noted during attempts to discontinue or taper the medicine.

Q: Does Estramon affect fertility?

Estradiol is a critical hormone for regulating the female reproductive system. While the product is not primarily a contraceptive, it is contraindicated during pregnancy. The official information does not define its direct effect on fertility outside of its indicated postmenopausal use.

Q: What is the intended duration of treatment with Estramon?

Official guidance states that treatment should be used for the shortest duration consistent with achieving treatment goals. Regulatory documents state that therapy should be periodically re-evaluated, often every three to six months, to assess the continued need for the medication.

Q: How is the safety profile of Estramon generally described?

The safety profile is characterized by an increased risk of serious health concerns, including cardiovascular disorders (like blood clots) and certain malignant neoplasms (cancers). Regulatory guidance requires balancing these serious risks with the benefits, using the lowest effective dose for the shortest time.

Q: Can Estramon be used by patients with diabetes?

Studies have examined the use of regulator-approved doses of transdermal HRT in women with type 2 diabetes. The evidence indicates that, over a period of up to five years, this treatment does not appear to be associated with an excess increased risk of cardiovascular complications in this patient group.

Q: What is the research status of Estramon—is it a new or established drug?

The active ingredient in Estramon, estradiol, is a naturally occurring, bioidentical hormone that is part of an established pharmacological class. The transdermal patch delivery system is a defined and commercially available prescription pharmaceutical.

Q: Are the reported side effects of Estramon typically mild?

While the most frequently reported side effects, such as headache and breast tenderness, are generally described as mild, the medicine carries an official warning about serious, life-threatening events. These serious risks, which include blood clots and certain cancers, must be considered in the overall risk-benefit assessment.

Q: What are the most common reasons patients discontinue using Estramon?

Clinical studies have examined the reasons patients attempt to discontinue hormone therapy. Commonly cited factors include physician recommendation, the experience of side effects, or a perceived lack of improvement in symptoms being treated.

Q: Does Estramon interact with herbal remedies or vitamins?

Official guidance notes that the herbal product St. John’s Wort is known to interact with hormone replacement therapies, potentially reducing the effectiveness of the treatment. Discussion of all herbal remedies and vitamin supplements with a healthcare provider is generally recommended.

Q: What is the general expectation for results after several months of use?

The general expectation is that hormone levels should stabilize and optimize within the first six months of use. To help assess effectiveness and safety, regular clinical monitoring is generally a component of the treatment protocol, often starting around three months and continuing annually once the dose is stable.

Q: Why is my doctor concerned about my blood pressure while using Estramon?

Cardiovascular risk is a required safety warning associated with systemic estrogen therapy. Monitoring blood pressure is necessary because high blood pressure can increase the risk of heart disease in postmenopausal women, and this must be assessed alongside the use of the medicine.

Q: Are there specific patient groups where Estramon is not studied?

Yes, the medicine has not been studied in all patient groups. Official documents state that safety and effectiveness have not been established in pediatric patients (children and adolescents). Additionally, individuals with severe liver impairment were excluded from clinical trials, meaning data for use in that population is not available.

Q: Is Estramon primarily a short-term or a long-term treatment option?

The official regulatory guidance does not define Estramon as strictly a short-term or a long-term option. Instead, it mandates that the treatment be used for the shortest duration necessary to meet individual treatment goals, with the need for continued therapy being periodically re-evaluated.

How should Estramon be stored and disposed of?

Storage and Disposal of Estramon Transdermal Patch

Estramon patches must be stored and disposed of according to specific regulatory mandates to ensure product stability and prevent accidental exposure to the active hormone.

Storage Requirements

Condition Requirement
Temperature Store below 25 C (77 F) in a closed container. Do not freeze or refrigerate.
Protection Keep in the original sealed pouch and carton, protected from direct light and moisture.
Safety Keep the medicine out of the sight and reach of children and pets.

Disposal Instructions

Used or expired patches still contain residual hormone and must be handled carefully. The used patch must be folded in half immediately, so the sticky sides adhere to each other. The folded patch should then be placed into a sturdy, child-proof container before being disposed of with household rubbish.

Do not flush the patches down the toilet or dispose of them in wastewater. Unused or outdated medicine should be handled according to local regulatory requirements or returned to a pharmacy.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Estramon found in:

A-Z Index: